Living with multiple sclerosis (MS) used to come with a much darker outlook. Decades ago, the disease often meant a shorter life and tougher challenges. But fast-forward to today, and things look way better. A remarkable long-term study spanning over 60 years from Norway’s Hordaland region has tracked patients diagnosed as far back as 1953 – and the results are encouraging: average survival time for people with MS has clearly gone up.
This isn’t just good news – it’s proof that advances in diagnosis, care, and treatments are making a real difference. While MS still shortens life compared to the general population (by about 7 years on average in this study), the gap is narrowing, and life expectancy is climbing. If you or someone you love deals with MS, this could bring real hope. Let’s dive into what the study found, why it’s happening, and what it means moving forward.
Also Read
The Power of a True Long-Term View: 60 Years of Data
Few studies go this far back. This one from the Hordaland province in western Norway is special because it follows an entire population-based cohort of MS patients starting from diagnoses in 1953 right up to recent years.
Researchers looked at 1,388 people with MS, tracking their survival and causes of death compared to the general population. They broke it down by time periods, disease type (like relapsing-remitting vs. primary progressive), gender, and more.
Key headline: Overall, people with MS had a median life expectancy of about 74.7 years, compared to 81.8 years in the matched general population – a difference of roughly 7 years.
But the trend over time? Survival has improved steadily. The standardized mortality ratio (SMR – how much higher death risk is compared to normal) dropped dramatically:
- For diagnoses/onset in 1953–1974: SMR around 3.0–3.1 (triple the risk)
- 1975–1996: Down to about 2.6–3.1
- 1997–2012: Much lower, around 0.7–0.8 (almost back to normal in later periods)
That’s a clear sign that modern approaches are closing the gap.
Breaking It Down: Survival by Gender, Disease Type, and More
Women generally fared better than men in the study – median life expectancy was 77.2 years for women with MS vs. 72.2 years for men (compared to higher averages in the general population too).
The type of MS made a big difference:
- Relapsing-remitting MS (RRMS, the most common form): Around 77.8 years life expectancy, with median survival from onset of 42.8 years
- Primary progressive MS (PPMS): Shorter at about 71.4 years, with only 25.5 years from onset
Cause of death? In most cases (about 56%), it was directly related to MS complications. But no major differences in other causes compared to the population.
Age at onset also played a role – those diagnosed young faced higher relative risks, while later-onset cases had risks closer to normal.
Why Survival Is Getting Better: The Real Reasons Behind the Progress
This improvement didn’t happen by accident. Over the decades, several things have changed for the better:
- Earlier and more accurate diagnosis (thanks to MRI and better criteria)
- Disease-modifying therapies (DMTs) that slow progression, reduce relapses, and protect the nervous system – especially since the 1990s
- Improved symptom management (for spasticity, fatigue, bladder issues, etc.)
- Better overall medical care, including for infections, mobility, and comorbidities
- Greater awareness and support, leading to earlier intervention
The study shows the biggest drops in excess mortality in the most recent periods (post-1997), which lines up with the arrival of effective DMTs and modern standards of care.
Other recent research supports this trend: MS life expectancy is normalizing in many places, with the gap now often 7–14 years shorter than average, but shrinking thanks to treatments.
What This Means for People Living with MS Today
The big message? MS is no longer the automatic sentence it once was. With today’s options, many people live long, full lives – especially if diagnosed early and treated promptly.
Relapsing forms respond best, so starting DMTs soon after diagnosis can make a huge difference. Even progressive forms are seeing more options emerge.
Challenges remain: MS still causes higher mortality overall, often from disease-related issues. But the trajectory is positive – survival is rising, and the excess risk is falling.
This 60-year perspective gives hope: Progress is real, measurable, and ongoing.
Looking Ahead: More Reasons for Optimism
With newer, highly effective therapies (like ocrelizumab, ofatumumab, and others), ongoing research into progressive MS, and better holistic care, experts expect survival to keep improving.
Prevalence is rising too – partly because people are living longer with the condition, meaning more older adults with MS in the future.
The takeaway? Stay informed, work closely with neurologists, and take advantage of modern treatments. The outlook is brighter than ever.
Have you or a loved one seen improvements in MS management over the years? What’s changed most for you? Share your thoughts below – stories like these inspire others.
